Pegzilarginase is a recombinant enzyme commercialized by Aeglea BioTherapeutics, with a leading Phase II program in Small-Cell Lung Cancer. According to Globaldata, it is involved in 8 clinical trials, of which 6 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Pegzilarginase’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Pegzilarginase is expected to reach an annual total of $36 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Pegzilarginase Overview

Pegzilarginase (AEB-1102) (AERase) is under development for the treatment of arginase I deficiency (Hyperargininemia), solid tumor, small cell lung cancer, cutaneous melanoma, uveal melanoma. It is administered intravenously. The drug candidate is a pegylated recombinant human arginase I. It is developed by substituting the cofactor manganese with cobalt. Recombinant arginase I act by degrading the amino acids arginine. It was under development for treatment of colon cancer, myelodysplastic syndrome, refractory and relapsed acute myeloid leukemia, hepatocellular carcinoma.

Aeglea BioTherapeutics Overview

Aeglea BioTherapeutics (Aeglea) is a biotechnology company. The company develops and commercializes human enzymes for the treatment of cancer and rare genetic diseases. The company’s lead product pipeline includes pegzilarginase (AEB1102), is used for the treatment of arginase deficiency. It also develops AGLE-177, for treating classical homocystinuria, a rare disease cause due to hereditary genetic deficiency; AGLE-324, for treating cystinuria. Aeglea also provides enzyme solutions to treat diseases with unmet medical needs. The company works in partnership with research institutions, healthcare providers and pharmaceutical companies. It caters its products across the US and the UK. Aeglea is headquartered in Austin, Texas, the US.

The company reported revenues of (US Dollars) US$18.7 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$65.7 million in FY2021, compared to an operating loss of US$81.5 million in FY2020. The net loss of the company was US$65.8 million in FY2021, compared to a net loss of US$80.9 million in FY2020. The company reported revenues of US$0.2 million for the third quarter ended September 2022, a decrease of 72.2% over the previous quarter.

For a complete picture of Pegzilarginase’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.